Literature DB >> 32294303

Preclinical comparative assessment of a dedicated pediatric poly-L-lactic-acid-based bioresorbable scaffold with a low-profile bare metal stent.

Kamel Shibbani1, Luiza De Lima E Silva Bagno2, Marie-France Poulin3, Thomas Matella4, Karim Diab4, Clifford Kavinsky4, Nagarajan Ramesh5, Vinayak Bhat5, Ziyad M Hijazi6, Damien Kenny7.   

Abstract

BACKGROUND: Polymer-based bioresorbable scaffolds (PBBS) have been assessed for coronary revascularization with mixed outcomes. Few studies have targeted pediatric-specific scaffolds. We sought to assess safety, efficacy, and short-term performance of a dedicated drug-free PBBS pediatric scaffold compared to a standard low-profile bare metal stent (BMS) in central and peripheral arteries of weaned piglets.
METHODS: Forty-two devices (22 Elixir poly-L-lactic-acid-based pediatric bioresorbable scaffolds [BRS] [6 × 18 mm] and 20 control BMS Cook Formula 418 [6 × 20 mm]) were implanted in the descending aorta and pulmonary arteries (PAs) of 14 female Yucatan piglets. Quantitative measurements were collected on the day of device deployment and 30 and 90 days postimplantation to compare device patency and integrity.
RESULTS: The BRS has a comparable safety profile to the BMS in the acute setting. Late lumen loss (LLL) and percent diameter stenosis (%DS) were not significantly different between BRS and BMS in the PA at 30 days. LLL and %DS were greater for BRS versus BMS in the aorta at 30 days postimplantation (LLL difference: 0.96 ± 0.26; %DS difference: 16.15 ± 4.51; p < .05). At 90 days, %DS in the aortic BRS was less, and PA BRS LLL was also less than BMS. Histomorphometric data showed greater intimal proliferation and area stenosis in the BRS at all time points and in all vessels.
CONCLUSIONS: A dedicated PBBS pediatric BRS has a favorable safety profile in the acute/subacute setting and demonstrates characteristics that are consistent with adult BRSs.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  bare metal stent; bioabsorbable devices/polymers; congenital heart disease, pediatrics; pediatric intervention; stent bioabsorbable

Mesh:

Substances:

Year:  2020        PMID: 32294303      PMCID: PMC7737646          DOI: 10.1002/ccd.28893

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  22 in total

1.  A novel design biodegradable stent for use in congenital heart disease: mid-term results in rabbit descending aorta.

Authors:  Surendranath R Veeram Reddy; Tré R Welch; Jian Wang; James A Richardson; Joseph M Forbess; Matthew Riegel; Alan W Nugent
Journal:  Catheter Cardiovasc Interv       Date:  2014-09-03       Impact factor: 2.692

2.  Angiography underestimates peripheral atherosclerosis: lumenography revisited.

Authors:  Vikram S Kashyap; Mircea L Pavkov; Paul D Bishop; Sean P Nassoiy; Matthew J Eagleton; Daniel G Clair; Kenneth Ouriel
Journal:  J Endovasc Ther       Date:  2008-02       Impact factor: 3.487

3.  Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.

Authors:  Gregory J Wilson; Gaku Nakazawa; Robert S Schwartz; Barbara Huibregtse; Bradley Poff; Thomas J Herbst; Donald S Baim; Renu Virmani
Journal:  Circulation       Date:  2009-06-29       Impact factor: 29.690

Review 4.  Bioresorbable Scaffold: The Emerging Reality and Future Directions.

Authors:  Yohei Sotomi; Yoshinobu Onuma; Carlos Collet; Erhan Tenekecioglu; Renu Virmani; Neal S Kleiman; Patrick W Serruys
Journal:  Circ Res       Date:  2017-04-14       Impact factor: 17.367

5.  OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold.

Authors:  Antonios Karanasos; Cihan Simsek; Muthukarrupan Gnanadesigan; Nienke S van Ditzhuijzen; Raphael Freire; Jouke Dijkstra; Shengxian Tu; Nicolas Van Mieghem; Gijs van Soest; Peter de Jaegere; Patrick W Serruys; Felix Zijlstra; Robert-Jan van Geuns; Evelyn Regar
Journal:  J Am Coll Cardiol       Date:  2014-12-01       Impact factor: 24.094

6.  First reported use of drug-eluting bioabsorbable vascular scaffold in congenital heart disease.

Authors:  B A McCrossan; C J McMahon; K P Walsh
Journal:  Catheter Cardiovasc Interv       Date:  2015-11-28       Impact factor: 2.692

7.  A novel biodegradable stent applicable for use in congenital heart disease: bench testing and feasibility results in a rabbit model.

Authors:  Surendranath R Veeram Reddy; Tre R Welch; Jian Wang; Frederic Bernstein; James A Richardson; Joseph M Forbess; Alan W Nugent
Journal:  Catheter Cardiovasc Interv       Date:  2013-08-08       Impact factor: 2.692

8.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model.

Authors:  R S Schwartz; K C Huber; J G Murphy; W D Edwards; A R Camrud; R E Vlietstra; D R Holmes
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

9.  Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies.

Authors:  Bill D Gogas; Maria Radu; Yoshinobu Onuma; Laura Perkins; Jennifer C Powers; Josep Gomez-Lara; Vasim Farooq; Hector M Garcia-Garcia; Roberto Diletti; Richard Rapoza; Renu Virmani; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2011-04-19       Impact factor: 2.357

10.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.

Authors:  Eliano Pio Navarese; Mariusz Kowalewski; David Kandzari; Alexandra Lansky; Bartosz Górny; Lukasz Kołtowski; Ron Waksman; Sergio Berti; Giuseppe Musumeci; Ugo Limbruno; Rene J van der Schaaf; Malte Kelm; Jacek Kubica; Harry Suryapranata
Journal:  Open Heart       Date:  2014-08-21
View more
  2 in total

Review 1.  Transcatheter Device Therapy and the Integration of Advanced Imaging in Congenital Heart Disease.

Authors:  Abhay A Divekar; Yousef M Arar; Stephen Clark; Animesh Tandon; Thomas M Zellers; Surendranath R Veeram Reddy
Journal:  Children (Basel)       Date:  2022-04-02

2.  Preliminary testing and evaluation of the renata minima stent, an infant stent capable of achieving adult dimensions.

Authors:  Evan M Zahn; Eason Abbott; Neil Tailor; Shyam Sathanandam; Dustin Armer
Journal:  Catheter Cardiovasc Interv       Date:  2021-05-04       Impact factor: 2.585

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.